Paris and London, November 29 (ots/PRNewswire) – Bristol-Myers Squibb Company and AstraZeneca announced today that the European Commission has granted marketing authorisation for KOMBOGLYZETM (saxagliptin and metformin HCl immediate-release fixed dose combination) that will cover the 27 Member States of the European Union. The indication for KOMBOGLYZE is as an adjunct to diet and exercise [...]
Tag Archive > Bristol Myers Squibb
European Commission Approves Labelling Update for REYATAZ® (atazanavir sulfate) in Pregnant Women Living With HIV
Paris, November 25 (ots/PRNewswire) – – REYATAZ(R) is the only boosted PI to include dosing and medical guidance in pregnancy and postpartum in the label – Bristol-Myers Squibb Company today announced that the European Commission approved a labelling update for REYATAZ(R) (atazanavir sulfate) based on new data generated in pregnant women living with HIV. The [...]
Thomson Reuters kürt die 100 innovativsten Unternehmen der Welt
London, November 15 (ots/PRNewswire) – Im vergangenen Jahr schufen die 100 innovativsten Organisationen der Welt insgesamt mehr als 400.000 neue Stellen und übertrafen die Umsätze der S&P 500 notierten Unternehmen um durchschnittlich 5,7 % Thomson Reuters startete heute das Programm Thomson Reuters 2011- Top 100 Global Innovator(SM) und kürte in diesem Rahmen die 100 innovativsten [...]
ots.Video: Wissen zählt: Drei neue Websites im Bereich Onkologie online
München (ots) – Ab sofort sind drei neue Websites mit Informationen zu verschiedenen Krebserkrankungen live: Neben einem übergeordneten Internetportal zu onkologischen Themen gibt es zwei weitere Websites zum schwarzen Hautkrebs (Melanom) und zur chronischen myeloischen Leukämie (CML). Krebspatienten, ihre Angehörigen und Interessierte können damit ihr Wissen über die Erkrankung vertiefen. www.bms-onkologie.de ist die unternehmensbezogene “Heimat” [...]
KOMBOGLYZE? (saxagliptin and metformin HCl Immediate-Release) Receives Positive CHMP Opinion in the European Union for the Treatment of Type 2 Diabetes
Paris and London (ots/PRNewswire) – Bristol-Myers Squibb Company and AstraZeneca today announced that the Marketing Authorisation Application for KOMBOGLYZE(TM) (saxagliptin and metformin HCl immediate-release fixed dose combination) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), as an adjunct to diet and exercise, for the treatment of type 2 diabetes [...]
Kurs zur Stabilitätsprüfung erobert das Format des Onlinetrainings im Sturm!
London (ots/PRNewswire) – 5 Module – 2 Wochen – alles wird aufgezeichnet und kann jederzeit angesehen werden! Pharma IQ freut sich, verkünden zu dürfen, dass der Online-Trainingskurs zur Stabilitätsprüfung sich als Schlüsselereignis in den Terminplänen der Pharmaindustrie erweist. Das Geheimnis hinter dem Erfolg des Online-Trainingskurses zur Stabilitätsprüfung ist neben dem Kursleiter – des Experten Dr. [...]
QIAGEN reicht zweiten US-Zulassungsantrag für Begleitdiagnostikum zur Anpassung von Darmkrebstherapien ein
Germantown, Maryland, und Hilden, Deutschland (ots) – - US-Gesundheitsbehörde FDA prüft therascreen® KRAS RGQ PCR-Test für die Verwendung mit Erbitux® (cetuximab), einem Krebsmedikament zur Behandlung von Patienten mit metastasierendem Darmkrebs. – PMA (Premarket Approval) folgt einem vorangegangenen Zulassungsantrag für den Einsatz mit einem weiteren EGFR-Inhibitor, ebenfalls bei Patienten mit metastasierendem Darmkrebs – QIAGEN erreicht Meilensteine [...]
YERVOY(TM) (ipilimumab) Approved for the Treatment of Previously-Treated Advanced Melanoma in the EU
Paris (ots/PRNewswire) – – First and Only Approved Therapy for Pre-treated Unresectable or Metastatic Melanoma to Demonstrate a Significant Improvement in Overall Survival – First EU-Approved Therapy for Pre-treated Unresectable or Metastatic Melanoma in More Than Two Decades Bristol-Myers Squibb today announced that the European Commission has approved YERVOY(TM) (ipilimumab) for the treatment of adult [...]
YERVOY? (ipilimumab) Approved for the Treatment of Previously-Treated Advanced Melanoma in the EU
Paris (ots/PRNewswire) – – First and Only Approved Therapy for Pre-treated Unresectable or Metastatic Melanoma to Demonstrate a Significant Improvement in Overall Survival – First EU-Approved Therapy for Pre-treated Unresectable or Metastatic Melanoma in More Than Two Decades Bristol-Myers Squibb today announced that the European Commission has approved YERVOY(TM) (ipilimumab) for the treatment of adult [...]
www.aktiv-mit-rheuma.de / Viele Tipps und breites Serviceangebot für Rheuma-Patienten jetzt online
München (ots) – Der Alltag für Patienten mit Rheumatoider Arthritis ist häufig geprägt durch Schmerzen und einer Einschränkung der Lebensqualität. Auf www.aktiv-mit-rheuma.de bietet das forschende pharmazeutische Unternehmen Bristol-Myers Squibb daher umfassende Informationen sowie multimediale Services, die Patienten mit der chronischen Gelenkerkrankung im Alltag unterstützen sollen. Arbeiten trotz Rheuma? Welcher Sport ist gut für mich? Was [...]
First-in-class Biologic Agent for Kidney Transplant Rejection Approved in Europe
Paris (ots/PRNewswire) – – European Commission approves NULOJIX(R) (belatacept), in combination with corticosteroids and a mycophenolic acid and an interleukin-2 receptor antagonist at induction, for prophylaxis of graft rejection in adult patients receiving a kidney transplant – First new mode of action for prevention of graft rejection in kidney transplantation in a decade – Similar [...]
Second Phase 3 Study of YERVOY(TM) (ipilimumab) in Metastatic Melanoma Meets Primary Endpoint of Overall Survival
Princeton, New Jersey (ots/PRNewswire) – – Study 024 Evaluated Newly-Diagnosed Patients Treated with YERVOY at Investigational Dose of 10mg/kg in Combination with Dacarbazine vs. Dacarbazine Alone – Forty-Seven Percent of Patients Treated with YERVOY Plus Dacarbazine Alive at One Year, 28 Percent Alive at Two Years and 20 Percent Alive at Three Years – In [...]
Bristol-Myers Squibb Receives CHMP Positive Opinion for YERVOY(TM) (ipilimumab) for Previously-Treated Patients With Metastatic Melanoma
Paris (ots/PRNewswire) – YERVOY (ipilimumab) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of patients with previously-treated unresectable or metastatic melanoma. The European Commission will consider the CHMP’s positive opinion in its decision on whether to grant a Marketing Authorisation by August 2011. “Despite the rising [...]
/C O R R E C T I O N — Bristol-Myers Squibb and AstraZeneca/
Paris and London (ots/PRNewswire) – In the news release, “ONGLYZA(R) Becomes the First DPP-4 Inhibitor Available for Use in Europe” issued on 4 Mar 2011 08:00 GMT, by Bristol-Myers Squibb and AstraZeneca NYSE:AZN over PR Newswire, we would like to advise that the headline was incorrectly transmitted by PR Newswire and should have read “ONGLYZA(R) [...]
ONGLYZA(R) Becomes the First DPP-4 Inhibitor Available for Use in Europe
Paris and London (ots/PRNewswire) – Bristol-Myers Squibb Company (http://www.bms.com) and AstraZeneca (http://www.astrazeneca.com) today announced that the European Commission has approved a label update for ONGLYZA(R) (saxagliptin) in the treatment of adults with type 2 diabetes who have moderate or severe renal impairment. The approved dosage for the patient group is a new once-daily 2.5 mg [...]
